• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ATAI Life Sciences N.V.

    3/1/22 4:30:22 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    ATAI Life Sciences N.V.

    (Name of Issuer)

     

    Common Shares

    (Title of Class of Securities)

     

    N0731H103

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. N0731H103

     

    (1)

    Names of reporting persons:

     

    Galaxy Group Funding (ECI) (U) LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

    (a) ☐

    (b) ☐

    (3)

    SEC use only

     

     

    (4)

    Citizenship or place of organization:

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person with

    (5)

    Sole voting power:

     

    0

    (6)

    Shared voting power:

     

    10,796,736

    (7)

    Sole dispositive power:

     

    0 

    (8)

    Shared dispositive power:

     

    10,796,736

    (9)

    Aggregate amount beneficially owned by each reporting person:

     

    10,796,736

    (10)

    Check if the aggregate amount in row (9) excludes certain shares (see instructions):

     

    ☐

    (11)

    Percent of class represented by amount in row (9):

     

    6.7%

    (12)

    Type of reporting person (see instructions):

     

    OO

     

     

     

     

    CUSIP No. N0731H103

     

    (1)

    Names of reporting persons:

     

    Galaxy Group Investments LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

    (a) ☐

    (b) ☐

    (3)

    SEC use only

     

     

    (4)

    Citizenship or place of organization:

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person with

    (5)

    Sole voting power:

     

    0

    (6)

    Shared voting power:

     

    10,796,736

    (7)

    Sole dispositive power:

     

    0

    (8)

    Shared dispositive power:

     

    10,796,736

    (9)

    Aggregate amount beneficially owned by each reporting person:

     

    10,796,736

    (10)

    Check if the aggregate amount in row (9) excludes certain shares (see instructions):

     

    ☐

    (11)

    Percent of class represented by amount in row (9):

     

    6.7%

    (12)

    Type of reporting person (see instructions):

     

    OO

     

     

     

     

    CUSIP No. N0731H103

     

    (1)

    Names of reporting persons:

     

    Michael E. Novogratz

    (2)

    Check the appropriate box if a member of a group (see instructions)

    (a) ☐

    (b) ☐

    (3)

    SEC use only

     

     

    (4)

    Citizenship or place of organization:

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person with

    (5)

    Sole voting power:

     

    0

    (6)

    Shared voting power:

     

    10,796,736

    (7)

    Sole dispositive power:

     

    0 

    (8)

    Shared dispositive power:

     

    10,796,736

    (9)

    Aggregate amount beneficially owned by each reporting person:

     

    10,796,736

    (10)

    Check if the aggregate amount in row (9) excludes certain shares (see instructions):

     

    ☐

    (11)

    Percent of class represented by amount in row (9):

     

    6.7%

    (12)

    Type of reporting person (see instructions):

     

    IN

     

     

     

     

    Item 1(a). Name of issuer:

     

    ATAI Life Sciences N.V. (the “Issuer”)

     

    Item 1(b). Address of issuer’s principal executive offices:

     

    ATAI Life Sciences N.V. c/o Mindspace

    Krausenstraße 9-10

    Berlin, Germany

     

    Item 2(a). Name of person filing:

     

    This Schedule 13G is being filed by: (i) Galaxy Group Funding (ECI) (U) LLC, a Delaware limited liability company (“GGF”), (ii) Galaxy Group Investments LLC, a Delaware limited liability company (“GGI”), and (iii) Michael E. Novogratz (all of the foregoing, collectively, the “Reporting Persons”). GGF is the holder of record of the Common Shares reported in this Schedule 13G. GGI is the manager of GGF and Michael E. Novogratz is the manager of GGI. GGI and Michael E. Novogratz may be deemed to share beneficial ownership of the Common Shares held of record by GGF.

     

    Item 2(b). Address of principal business office or, if none, residence:

     

    The principal business office of the Reporting Persons is:

     

    107 Grand Street, 7th Floor

    New York, NY 10013

     

    Item 2(c). Citizenship:

     

    GGF and GGI are limited liability companies organized in Delaware.

     

    Michael E. Novogratz is a United States citizen.

     

    Item 2(d). Title of Class of Securities:

     

    Common Shares, par value €0.10 per share (“Common Shares”)

     

    Item 2(e). CUSIP No.:

     

    N0731H103

     

    Item 3.

     

    Not Applicable.

     

    Item 4. Ownership

     

    The ownership information below represents beneficial ownership by the Reporting Persons of the Common Shares of the Issuer as of December 31, 2021, based upon 160,297,952 Common Shares outstanding as of November 1, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q for the period ended September 30, 2021 filed with the Securities and Exchange Commission on November 15, 2021.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable.

     

     

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification

     

    Not Applicable.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Document
         
    99.1   Joint Filing Agreement, dated February 22, 2022, among the Reporting Persons

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Galaxy Group Funding (ECI) (U) LLC
         
    February 22, 2022 By: /s/ Vincent Barbuto
      Name: Vincent Barbuto
      Title: Chief Financial Officer
         
      Galaxy Group Investments LLC
         
    February 22, 2022 By: /s/ Vincent Barbuto
      Name: Vincent Barbuto
      Title: Chief Financial Officer
         
    February 22, 2022 By: /s/ Michael E. Novogratz
      Name: Michael E. Novogratz

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

     

     

     

    Get the next $ATAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATAI

    DatePrice TargetRatingAnalyst
    4/4/2025Buy
    Berenberg
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    4/3/2024$6.00Hold → Buy
    Maxim Group
    11/1/2022$18.00Buy
    Loop Capital
    11/30/2021$25.00Buy
    Maxim Group
    11/22/2021$40.00 → $50.00Buy
    HC Wainwright & Co.
    11/16/2021$25.00 → $24.00Outperform
    Credit Suisse
    11/16/2021$19.00 → $17.00Sector Perform
    RBC Capital
    More analyst ratings

    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

      With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments Anticipate topline data midyear from the Phase 2b clinical trial of BPL-003 in patients with treatment-resistant depression (TRD) - the largest controlled trial of mebufotenin and the first and only such trial to investigate mebufotenin in the U.S.Dosed the first patient in the exploratory Phase 2 study of EMP-01 (oral R-MDMA) for the treatment of social anxiety; topline data anticipated in Q1'26Continued enrollment in Elumina, a Phase 2 study of VLS-01 (buccal film DMT) in patients with TRD; topline data are anticipated in Q1'26 Cash, cas

      5/14/25 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

      - In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA - The exploratory, randomized, double-blind, placebo-controlled Phase 2 study will assess the safety, tolerability and efficacy of EMP-01 in adults with social anxiety disorder - Topline data anticipated in the first quarter of 2026 NEW YORK and BERLIN, May 13, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announce

      5/13/25 7:01:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

       - Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1'26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social anxiety disorder; topline data anticipated in Q1'26 - Beckley Psytech completed enrollment in the Phase 2b study of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression; topline data anticipated in mid-25 - Completed an equity offering with net proceeds of $59.2 million; extending operational runway into 2027 NEW YORK and BERLIN, March 17, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("a

      3/17/25 8:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.

      SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

      9/27/24 7:56:26 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

      SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

      5/3/24 4:06:02 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

      SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

      3/12/24 9:30:31 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Apeiron Investment Group Ltd. bought $2,520,000 worth of shares (1,800,000 units at $1.40) (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      3/24/25 5:00:18 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Apeiron Investment Group Ltd. bought $22,755,008 worth of shares (10,835,718 units at $2.10) (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      2/19/25 6:00:05 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brand Florian bought $23,120 worth of shares (20,000 units at $1.16), increasing direct ownership by 18% to 130,000 units (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      11/20/23 9:17:41 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    SEC Filings

    See more
    • SEC Form 10-Q filed by ATAI Life Sciences N.V.

      10-Q - ATAI Life Sciences N.V. (0001840904) (Filer)

      5/14/25 4:18:00 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ATAI Life Sciences N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ATAI Life Sciences N.V. (0001840904) (Filer)

      5/14/25 7:10:19 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ATAI Life Sciences N.V. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation

      8-K - ATAI Life Sciences N.V. (0001840904) (Filer)

      5/8/25 4:16:17 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Leadership Updates

    Live Leadership Updates

    See more
    • atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

      - Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.

      1/10/25 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

      NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati

      5/23/24 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

      NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off

      2/6/24 5:00:31 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Financials

    Live finance-specific insights

    See more
    • atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

      Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai's existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24 BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects Anticipated synergies th

      1/4/24 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform

      –   Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101, GRX-917 and DMX-1002, and successful completion of 2 cohorts in the Introspect Digital Therapeutics ketamine trials –   Eight new programs added to platform since January 2021 bringing total, as of today, to 13 discovery and drug development programs and four enabling technologies –   Ended 2021 very well capitalized with $362 million to execute our strategy to achieve clinically meaningful and sustai

      3/30/22 6:59:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update

      NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update. To access the webcast, please log in at https://wsw.com/webcast/cc/atai/1358298. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life. About atai Life Sciences atai was founded in 2018 as a response to the significant

      3/23/22 6:59:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Short Glenn Frank sold $17,767 worth of shares (13,161 units at $1.35), decreasing direct ownership by 24% to 42,333 units (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      3/24/25 9:00:05 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Kirpekar Sahil sold $65,560 worth of shares (48,563 units at $1.35), decreasing direct ownership by 30% to 115,636 units (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      3/24/25 9:00:11 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Johnson Anne Nagengast sold $45,286 worth of shares (33,545 units at $1.35), decreasing direct ownership by 19% to 140,045 units (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      3/24/25 9:00:06 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berenberg initiated coverage on atai Life Sciences N.V.

      Berenberg initiated coverage of atai Life Sciences N.V. with a rating of Buy

      4/4/25 8:27:07 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on atai Life Sciences N.V. with a new price target

      H.C. Wainwright reiterated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $10.00 from $15.00 previously

      11/18/24 11:31:29 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences N.V. upgraded by Maxim Group with a new price target

      Maxim Group upgraded atai Life Sciences N.V. from Hold to Buy and set a new price target of $6.00

      4/3/24 8:14:20 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care